- Market Capitalization, $K 89,491
- Shares Outstanding, K 11,980
- Annual Sales, $ 10 K
- Annual Income, $ -30,060 K
- 60-Month Beta 2.38
- Price/Sales 15,194.63
- Price/Cash Flow N/A
- Price/Book 0.85
|Period||Period Low||Period High||Performance|
| || |
-0.43 (-5.44%)since 05/24/19
| || |
-0.93 (-11.07%)since 03/26/19
| || |
-4.13 (-35.60%)since 06/26/18
Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019
A single intravitreal injection of 125 Î¼g CB 2782-PEG achieved complete, rapid and sustained pharmacodynamic inhibition (>99%) of complement factor 3 (C3) in non-human primates (NHP), supporting dosing...
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CBRE Group, Inc. (NYSE:CBRE),...
Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare...
Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX)...
Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has awarded orphan designation of its Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for the treatment...
Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical efficacy, with >90% reduction in bleeding
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omega Healthcare Investors,...
Results from the study demonstrate that subcutaneous MarzAA (FVIIa) significantly reduces both annualized bleed rate and the percentage of days with bleeding
Results show a four-fold reduction in bleeding time for CB 2679d-GT and a three-fold improvement in clotting activity when compared with an AAV-encoding Padua vector